IN8BIO, INC. Files 8-K: Material Agreement, Equity Sales
Ticker: INAB · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2025 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.0001, $1.38, $1.3799, $20.1 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, equity-sale, financial-statements
TL;DR
IN8BIO signed a big deal and sold some stock, filing it all today.
AI Summary
On December 18, 2025, IN8bio, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing was made on December 19, 2025.
Why It Matters
This 8-K filing indicates IN8bio, Inc. has entered into a significant agreement and has engaged in equity transactions, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — Material definitive agreements and unregistered equity sales can introduce financial and operational risks for a company.
Key Players & Entities
- IN8BIO, INC. (company) — Registrant
- December 18, 2025 (date) — Date of earliest event reported
- December 19, 2025 (date) — Filing date
FAQ
What type of material definitive agreement did IN8bio, Inc. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on December 18, 2025.
What was the purpose of the unregistered sales of equity securities?
The filing mentions unregistered sales of equity securities but does not provide details on the purpose or the specific terms of these sales.
Are the financial statements and exhibits filed with this 8-K detailed?
The filing indicates that financial statements and exhibits are included, but their specific content and detail are not described in the provided text.
Has IN8bio, Inc. had a name change previously?
Yes, the company was formerly known as Incysus Therapeutics, Inc., with a name change date of May 10, 2018.
What is IN8bio, Inc.'s primary business sector?
IN8bio, Inc. operates in the Biological Products (No Diagnostic Substances) sector, with SIC code 2836.
Filing Stats: 2,074 words · 8 min read · ~7 pages · Grade level 16.4 · Accepted 2025-12-19 17:22:35
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share INAB The Nasdaq
- $1.38 — of Common Stock, at a purchase price of $1.38 per Share (the "Share Price"), and, in
- $1.3799 — Warrant Shares, at a purchase price of $1.3799 per Pre-Funded Warrant (the "Pre-Funded
- $20.1 m — gregate gross proceeds of approximately $20.1 million, before deducting placement agent
Filing Documents
- d145007d8k.htm (8-K) — 40KB
- d145007dex41.htm (EX-4.1) — 78KB
- d145007dex101.htm (EX-10.1) — 230KB
- d145007dex102.htm (EX-10.2) — 145KB
- 0001193125-25-327097.txt ( ) — 726KB
- inab-20251218.xsd (EX-101.SCH) — 3KB
- inab-20251218_lab.xml (EX-101.LAB) — 18KB
- inab-20251218_pre.xml (EX-101.PRE) — 11KB
- d145007d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Pre-Funded Warrant 10.1* Securities Purchase Agreement, dated as of December 18, 2025. 10.2 Registration Rights Agreement, dated as of December 18, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will supplementally furnish copies of omitted schedules and exhibits to the SEC or its staff upon its request.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IN8bio, Inc. Date: December 19, 2025 By: /s/ Patrick McCall Patrick McCall Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)